Patients with JIA, specifically the polyarticular subtype, may present with temporomandibular joint arthritis. Given the pain typically present in the joint, limitations in opening may be noted. As such, oral health and hygiene practices may be compromised in this patient population. Dental management considerations during treatment include shorter visits, safe measures to maintain mouth opening, frequent breaks during procedures, and counselling on condition management to reduce risks in the future. In dental extractions, bite blocks or props may be used to complete the procedure safely and reduce pain.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cden.2023.06.001DOI Listing

Publication Analysis

Top Keywords

patient juvenile
4
juvenile idiopathic
4
idiopathic arthritis
4
arthritis presents
4
presents dental
4
dental extraction
4
extraction patients
4
patients jia
4
jia polyarticular
4
polyarticular subtype
4

Similar Publications

Calcinosis is an intractable condition in juvenile dermatomyositis. The effect of abatacept on calcinosis remains controversial. We describe a case of an 8-year-old boy in whom the addition of abatacept to mycophenolate mofetil was effective against calcinosis in juvenile dermatomyositis.

View Article and Find Full Text PDF

We present the first reported case of an isolated small-bowel intestinal juvenile polyp in an adult. This case is particularly noteworthy as it was asymptomatic, detected via computed tomography, localized by capsule endoscopy, and successfully resected via double-balloon endoscopy before the development of acute symptoms.

View Article and Find Full Text PDF

Objective: Acromegaly is an endocrine disorder caused by the hypersecretion of growth hormone (GH) by a benign tumor of the pituitary that leads to insulin-like growth factor-1 (IGF1) overproduction. In most patients, somatostatin analogs (SSAs), the current first line medical therapy for acromegaly, do not normalize IGF1 levels. This study aims to investigate the pre-clinical efficacy of ALXN2420, a novel, small peptide antagonist of the growth hormone receptor (GHR), being developed as a combination therapy to SSAs to further suppress and normalize IGF1 levels.

View Article and Find Full Text PDF

miR-708-5p is elevated in bipolar patients and can induce mood disorder-associated behavior in mice.

EMBO Rep

March 2025

Laboratory of Systems Neuroscience, Institute for Neuroscience, Department of Health Science and Technology, ETH Zurich, 8057, Zurich, Switzerland.

Mood disorders (MDs) are caused by an interplay of genetic and environmental (GxE) risk factors. However, molecular pathways engaged by GxE risk factors are poorly understood. Using small-RNA sequencing in peripheral blood mononuclear cells (PBMCs), we show that the bipolar disorder (BD)-associated microRNA miR-708-5p is upregulated in healthy human subjects with a high genetic or environmental predisposition for MDs.

View Article and Find Full Text PDF

Sarcopenia is a disease characterized by decreasing muscle mass and strength or performance. The prevalence of sarcopenia in rheumatic diseases has been evaluated in single diseases using various diagnostic approaches, generating conflicting data. The study aims to investigate sarcopenia prevalence in young adults with inflammatory arthritis (IA) and to detect factors associated with low muscle mass and strength.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!